International Stem Cell director sells 32.8K shares at $0.32

International Stem Cell CORP (ISCO) director Paul V. Maier reported an indirect sale of common stock held through a family trust.

Rhea-AI Filing Summary

International Stem Cell CORP (ISCO) director Paul V. Maier reported an indirect sale of common stock held through a family trust. On September 11, 2026, the trust sold 32,802 shares of ISCO common stock at $0.32 per share, and the filing reports that no shares remain held indirectly after this transaction. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 32,802 shares

Net Sell 1 txn

Insider MAIER PAUL V

Role Director

Sold 32,802 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Common Stock	32,802	$0.32	$10K

Holdings After Transaction: Common Stock — 0 shares (Indirect, Through family Trust dated 4/21/2000)

Key Figures

Shares sold: 32,802 shares Sale price per share: $0.32 per share Shares held indirectly after transaction: 0 shares +1 more

4 metrics

Shares sold 32,802 shares Indirect sale of ISCO common stock on September 11, 2026

Sale price per share $0.32 per share Price for the 32,802 ISCO shares sold on September 11, 2026

Shares held indirectly after transaction 0 shares Indirect holdings through the family trust following the sale

Net shares sold 32,802 shares Net sell direction across all transactions in this Form 4

Key Terms

indirect ownership, Rule 10b5-1, family Trust

3 terms

indirect ownership financial

"The ownership type is reported as indirect through a family trust"

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox is not affirmed for these transactions"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

family Trust financial

"Nature of ownership is described as Through family Trust dated 4/21/2000"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ISCO director Paul V. Maier report?

Paul V. Maier reported an indirect sale of ISCO common stock held through a family trust. On September 11, 2026, the trust sold 32,802 shares of common stock.

At what price were the ISCO shares sold in Paul V. Maier’s Form 4?

The filing states that 32,802 shares of International Stem Cell CORP (ISCO) common stock were sold at a price of $0.32 per share on September 11, 2026.

How many ISCO shares does Paul V. Maier report holding after this transaction?

After the reported transaction, the Form 4 shows 0 shares of ISCO common stock held indirectly through the referenced family trust following the sale of 32,802 shares.

Was Paul V. Maier’s ISCO share sale under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not affirmed, meaning the reported sale was not disclosed as made under a Rule 10b5-1 trading plan.

Were the ISCO shares sold by Paul V. Maier held directly or indirectly?

The shares were held indirectly. The Form 4 describes the ownership nature as “Through family Trust dated 4/21/2000,” indicating the transaction was by a family trust associated with Paul V. Maier.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:13 PM Accepted by SEC EDGAR 09/15/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAIER PAUL V

(Last) (First) (Middle)

C/O INTERNATIONAL STEM CELL CORP.

9745 BUSINESSPARK AVE.

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
International Stem Cell CORP [ ISCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S		32,802	D	$0.32	0	I	Through family Trust dated 4/21/2000

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Paul V. Maier	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)